Cardinal Health(US:CAH) ZACKSยท2025-05-01 14:36Core Insights - Cardinal Health reported revenue of $54.88 billion for the quarter ended March 2025, a slight decrease of 0.1% year-over-year, with an EPS of $2.35, up from $2.08 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $55.03 billion by 0.27%, while the EPS exceeded the consensus estimate of $2.15 by 9.30% [1] Financial Performance Metrics - Revenue from Pharmaceutical and Specialty Solutions was $50.43 billion, slightly above the average estimate of $50.33 billion, reflecting a year-over-year decline of 0.4% [4] - Revenue from Other segments was reported at $1.30 billion, slightly exceeding the estimated $1.29 billion [4] - Revenue from Medical Products and Distribution was $3.16 billion, below the average estimate of $3.21 billion, but showed a year-over-year increase of 1.5% [4] - Segment profit for Pharmaceutical and Specialty Solutions was $662 million, surpassing the estimated $635.77 million [4] - Segment profit for Other was $134 million, exceeding the average estimate of $119.24 million [4] - Segment profit for Global Medical Products and Distribution was $39 million, below the average estimate of $44.16 million [4] Stock Performance - Cardinal Health's shares have returned +1.9% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]